Skip navigation
Universidade Federal da Bahia |
Repositório Institucional da UFBA
Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/39106
Registro completo de metadados
Campo DCValorIdioma
dc.creatorPaixão, Jose Carlos Santiago da-
dc.date.accessioned2024-02-27T15:43:07Z-
dc.date.available2024-02-27T15:43:07Z-
dc.date.issued2024-01-16-
dc.identifier.citationPAIXÃO, José Carlos Santiago da. Estudo descritivo da população atendida no ambulatório de hipertensão pulmonar do HUPES/UFBA. Orientadora: Nélia Cláudia Neri Araújo. 2024. 29 f. Trabalho de Conclusão de Curso (Especialização em Pneumologia) - Universidade Federal da Bahia, Complexo Hospitalar Universitário Professor Edgard Santos, Programa de Residência Médica, Salvador, 2024.pt_BR
dc.identifier.urihttps://repositorio.ufba.br/handle/ri/39106-
dc.description.abstractIntroduction: Pulmonary hypertension (PH) is a progressive chronic disease, commonly subdiagnosed, capable of generating serious systemic repercussions that impacts on the individual's functional capacity, and quality of life. Objectives: describe clinical and hemodynamic aspects of patients with PH followed at the pulmonology outpatient clinic of the Professor Edgard Santos University Hospital (HUPES), with an emphasis on severity criteria and adopted therapies. Methods: this is a retrospective descriptive study of patients with the age over 18 years, who had a diagnosis of PH and has been treated at the HUPES reference outpatient clinic between January 2021 and August 2023. For inclusion criteria was necesary that the patient underwent right heart catheterization, and presented the results. All the data used in this study was obtained through review of eletronical medical records. Results: the study was conducted through a total sample of 116 individuals, with a predominance of females, 69.2%, and an average age of 52.2 years. Mean Pulmonary Artery Pressure had a median of 40.5 mmHg, and the median of pulmonary vascular resistance was 5.25 Woods. 35.9% of the study population was in the low risk category for PH, while only 2.6% was at high risk. 18.8% of individuals required home oxygen therapy. The main comorbidity among the individuals studied was Systemic Arterial Hypertension presented in 41.9%. The most used medication among study participants was Sidenafil / Tadalafil, used by 64.1% of the sample, as monotherapy or in combination. The main group of PH in the sample was Group I with 59%, whose main underlying cause was congenital heart disease. Regarding therapy, 15.9% of patients in this group did not use any drug to treat PH, while 42% continued on single drug therapy, and 39% used Sidenafil / Tadalafil and Bosentana / Ambrisentana as a combination. Conclusion: The predominance of women and the severity demonstrated by hemodynamic parameters and functional tests emphasize the need for a careful and personalized clinical approach. Furthermore, the coexistence of several comorbidities highlights the complexity of PH management and the importance of comprehensive therapeutic strategies.pt_BR
dc.languageporpt_BR
dc.publisherHospital Universitário Professor Edgar Santospt_BR
dc.subjectPneumologiapt_BR
dc.subjectHipertensão pulmonarpt_BR
dc.subjectHipertensão arterial pulmonarpt_BR
dc.subjectTerapêuticapt_BR
dc.subject.otherPulmonary Medicinept_BR
dc.subject.otherHypertension, Pulmonarypt_BR
dc.subject.otherPulmonary Arterial Hypertensionpt_BR
dc.subject.otherTherapeuticspt_BR
dc.titleEstudo descritivo da população atendida no ambulatório de hipertensão pulmonar do HUPES/UFBApt_BR
dc.title.alternativeDescriptive study of the population treated at the pulmonary hypertension outpatient clinic at HUPES/UFBApt_BR
dc.typeTrabalho de Conclusão de Cursopt_BR
dc.publisher.initialsHUPESpt_BR
dc.publisher.countryBrasilpt_BR
dc.subject.cnpqCNPQ::CIENCIAS DA SAUDEpt_BR
dc.subject.cnpqCNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICApt_BR
dc.subject.cnpqCNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::PNEUMOLOGIApt_BR
dc.contributor.advisor1Araújo, Nélia Claudia Neri-
dc.contributor.advisor1IDhttps://orcid.org/0000-0001-7060-0376pt_BR
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/2646137676277693pt_BR
dc.contributor.referee1Araújo, Nélia Cláudia Neri-
dc.contributor.referee1IDhttps://orcid.org/0000-0001-7060-0376pt_BR
dc.contributor.referee1Latteshttp://lattes.cnpq.br/2646137676277693pt_BR
dc.creator.IDhttps://orcid.org/0009-0004-4661-2237pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/3679878118341194pt_BR
dc.description.resumoIntrodução: A hipertensão pulmonar (HP) é uma doença crônica progressiva, pouco diagnosticada, capaz de gerar repercussões sistêmicas graves e interferir na capacidade funcional e qualidade de vida do indivíduo. Objetivos: descrever aspectos clínicos e hemodinâmicos dos pacientes com HP acompanhados no ambulatório de pneumologia do Hospital Universitário Professor Edgard Santos (HUPES), com ênfase em critérios de gravidade e terapêuticas adotadas. Métodos: estudo descritivo retrospectivo de pacientes com idade superior a 18 anos, que possuíam o diagnóstico de HP atendidos no ambulatório de referência do HUPES entre janeiro de 2021 até agosto de 2023, que realizaram cateterismo cardíaco direito, com dados obtidos através da revisão de prontuários eletrônicos. Resultados: a amostra foi composta por 116 indivíduos, com predominância do sexo feminino, 69,2%, e média de idade de 52,2 anos. A Pressão Média da Artéria Pulmonar apresentou uma mediana de 40,5 mmHg, e a resistência vascular pulmonar 5,25 Woods. 35,9% da população estudada se encontrava na categoria de baixo risco de HP, enquanto apenas 2,6% eram de alto risco. 18,8% dos indivíduos necessitavam de oxigenioterapia domiciliar. A principal comorbidade entre os indivíduos estudados foi a HAS, em 41,9%. O medicamento mais utilizado entre os participantes do estudo foi a Sidenafila / Tadalafila, usada por 64,1% da amostra, como monoterapia ou em associação. O principal grupo de HP na amostra foi o Grupo I com 59%, cuja principal causa base foram as cardiopatias congênitas. Quanto a terapêutica, 15,9% dos pacientes deste grupos não faziam uso de nenhuma droga para tratamento da HP, enquanto 42% seguiam em terapia medicamentosa única e 39% usavam Sidenafila ou Tadalafila e Bosentana ou Ambrisentana em combinação. Conclusão: A predominância de mulheres e a severidade demonstrada pelos parâmetros hemodinâmicos e testes funcionais enfatizam a necessidade de uma abordagem clínica cuidadosa e personalizada. Ademais, a coexistência de diversas comorbidades sublinha a complexidade do manejo da HP e a importância de estratégias terapêuticas abrangentespt_BR
dc.publisher.departmentFaculdade de Medicina da Bahiapt_BR
dc.relation.referencesSimonneau, G., Montani, D., Celermajer, D. S., et al. (2019). Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 53(1), 1801913. https://doi.org/10.1183/13993003.01913-2018 - 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2. Marc Humbert, Gabor Kovacs, Marius M. Hoeper, Roberto Badagliacca, Rolf M.F. Berger, Margarita Brida, Jørn Carlsen, Andrew J.S. Coats, Pilar Escribano-Subias, Pisana Ferrari, Diogenes S. Ferreira, Hossein Ardeschir Ghofrani, George Giannakoulas, David G. Kiely, Eckhard Mayer, Gergely Meszaros, Blin Nagavci, Karen M. Olsson, Joanna Pepke-Zaba, Jennifer K. Quint, Göran Rådegran, Gerald Simonneau, Olivier Sitbon, Thomy Tonia, MarkToshner, JeanLuc Vachiery, Anton Vonk Noordegraaf, Marion Delcroix, Stephan Rosenkranz, the ESC/ERS Scientific Document Group. European Respiratory Journal Jan 2023, 61 (1) 2200879; DOI: 10.1183/13993003.00879-2022 3. Ramos RP, et al. "Benefícios e limitações do tratamento atual da hipertensão arterial pulmonar". Rev Soc Cardiol Estado de São Paulo, 2011. 4. Souza R, et al. "Análise contemporânea da história natural da hipertensão arterial pulmonar". Rev Soc Cardiol Estado de São Paulo, 2011. 5. The importance of the World Symposium on Pulmonary Hypertension / A importância do Simpósio Mundial de Hipertensão Pulmonar Jardim, Carlos; Waetge, Daniel. J. bras. pneumol ; 44(3): 173-174, May-June 2018.http://dx.doi.org/10.1590/S1806-37562018000030001 6. Fernandes CJ, Calderaro D, Assad APL, Salibe-Filho W, KatoMorinaga LT, Hoette S, Piloto B, Castro MA, Lisboa RP, Silva TAFD, Martins MA, Alves-Jr JL, Jardim C, Terra-Filho M, Souza R. Update on the Treatment of Pulmonary Arterial Hypertension. Arq Bras Cardiol. 2021 Oct;117(4):750-764. English, Portuguese. doi: 10.36660/abc.20200702. PMID: 34709302; PMCID: PMC8528352. 7. Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park DH, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Lange TJ, Rosenkranz S. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022 Jul 7;60(1):2102311. doi: 10.1183/13993003.02311-2021. PMID: 34737226; PMCID: PMC9260123. 8. McLaughlin, V. V., Archer, S. L., Badesch, D. B., et al. (2019). ACC/AHA 2018 multisociety guideline on the diagnosis, evaluation, 27 and treatment of pulmonary hypertension. Journal of the American College of Cardiology, 73(24), e165-e191. https://doi.org/10.1016/j.jacc.2018.10.107 9. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec;130(6):1657-63. doi: 10.1378/chest.130.6.1657. PMID: 17166979. 10. Lopes AA, Barst RJ, Haworth SG, Rabinovitch M, Al Dabbagh M, Del Cerro MJ, Ivy D, Kashour T, Kumar K, Harikrishnan S, D'Alto M, Thomaz AM, Zorzanelli L, Aiello VD, Mocumbi AO, Santana MV, Galal AN, Banjar H, Tamimi O, Heath A, Flores PC, Diaz G, Sandoval J, Kothari S, Moledina S, Gonçalves RC, Barreto AC, Binotto MA, Maia M, Al Habshan F, Adatia I. Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulm Circ. 2014 Jun;4(2):330-41. doi: 10.1086/675995. Erratum in: Pulm Circ. 2014 Sep;4(3):531. PMID: 25006452; PMCID: PMC4070778. 11. Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev. 2010 Mar;19(115):59-63. doi: 10.1183/09059180.00007309. PMID: 20956167; PMCID: PMC9491634. 12. Barnes H, Yeoh HL, Fothergill T, Burns A, Humbert M, Williams T. Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2019 May 1;5(5):CD012785. doi: 10.1002/14651858.CD012785.pub2. PMID: 31042010; PMCID: PMC6492481. 13. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. PMID: 26699168. 14. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, doubleblind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10;117(23):3010-9. doi: 10.1161/CIRCULATIONAHA.107.742510. Epub 2008 May 27. PMID: 18506008. 15. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension 28 (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17;353(20):2148-57. doi: 10.1056/NEJMoa050010. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1. PMID: 16291984. 16. Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016 Apr;4(4):291-305. doi: 10.1016/S2213-2600(16)00027-8. Epub 2016 Feb 27. Erratum in: Lancet Respir Med. 2016 Jun;4(6):e34. PMID: 26935844. 17. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016 Mar 21;37(12):942-54. doi: 10.1093/eurheartj/ehv512. Epub 2015 Oct 27. PMID: 26508169; PMCID: PMC4800173. 18. Caravita S, Dewachter C, Soranna D, D'Araujo SC, Khaldi A, Zambon A, Parati G, Bondue A, Vachiéry JL. Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a metaanalysis. Eur Respir J. 2018 Apr 4;51(4):1702427. doi: 10.1183/13993003.02427-2017. PMID: 29439019. 19. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019 Jan 24;53(1):1801914. doi: 10.1183/13993003.01914-2018. PMID: 30545980; PMCID: PMC6351338. 20. Blanco I, Santos S, Gea J, Güell R, Torres F, Gimeno-Santos E, Rodriguez DA, Vilaró J, Gómez B, Roca J, Barberà JA. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J. 2013 Oct;42(4):982-92. doi: 10.1183/09031936.00176312. Epub 2013 Feb 21. PMID: 23429918. 21. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, Jenkins D, Kim NH, Humbert M, Jais X, Vonk Noordegraaf A, Pepke-Zaba J, Brénot P, Dorfmuller P, Fadel E, Ghofrani HA, Hoeper MM, Jansa P, Madani M, Matsubara H, Ogo T, Grünig E, D'Armini A, Galie N, Meyer B, Corkery P, Meszaros G, Mayer E, Simonneau G. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021 Jun 17;57(6):2002828. doi: 10.1183/13993003.028282020. PMID: 33334946. 22. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. PMID: 31504429.pt_BR
dc.type.degreeEspecializaçãopt_BR
dc.publisher.courseMEDICINApt_BR
Aparece nas coleções:Trabalho de Conclusão de Curso (Especialização) - Programa de Residência Médica (PRM)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
TCC PNEUMOLOGIA JOSE CARLOS FINAL.pdf1,05 MBAdobe PDFVisualizar/Abrir
APROVACAO TCC JOSE FINAL.pdf178,74 kBAdobe PDFVisualizar/Abrir
Ficha 1 - TCC JOSE FINAL COREME.pdf225,11 kBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.